Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efbemalenograstim Alfa for Prevention of Febrile Neutropenia in NSCLC
NCT06143735Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efbemalenograstim alfa in febrile neutropenia (FN), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT06143735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143735.